Compare NGVT & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGVT | SRPT |
|---|---|---|
| Founded | 1964 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | 2015 | 2000 |
| Metric | NGVT | SRPT |
|---|---|---|
| Price | $76.61 | $22.16 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 29 |
| Target Price | ★ $72.50 | $25.85 |
| AVG Volume (30 Days) | 262.1K | ★ 3.2M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.10 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,167,600,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $3.63 | N/A |
| Revenue Next Year | $0.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $30.19 | $10.42 |
| 52 Week High | $77.46 | $64.80 |
| Indicator | NGVT | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 68.42 | 59.45 |
| Support Level | $63.60 | $20.61 |
| Resistance Level | $77.23 | $23.55 |
| Average True Range (ATR) | 1.97 | 1.48 |
| MACD | 0.75 | 0.06 |
| Stochastic Oscillator | 94.58 | 64.47 |
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The Company generates the majority of its revenue from North America.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.